Prothena (PRTA) CSO Zago Wagner Sells 51,000 Shares

What Happened Zago Wagner, Chief Scientific Officer of Prothena (PRTA), had 51,000 restricted stock units (RSUs) convert to ordinary shares on July 28, 2026 and those 51,000 shares were then transferred to the issuer (disposition) at $8.56 per share, generating $436,560. The filing shows the RSUs converted (derivative exercise/conversion with $0 exercise price) and the resulting shares were surrendered to the company; this type of transaction is commonly used to satisfy tax withholding obligations rather than an open-market sale.

Key Details

• Transaction date: July 28, 2026; Form 4 filed July 30, 2026 (timely filing).
• Conversion/exercise: 51,000 RSUs converted into shares (derivative conversion, reported with $0 exercise price).
• Disposition: 51,000 shares transferred to issuer at $8.56 per share for total proceeds of $436,560.
• Shares owned after transaction: not specified in the supplied excerpt of the filing—consult the full Form 4 for post-transaction beneficial ownership.
• Footnotes:
  • F1: Each RSU equals the contingent right to one ordinary share on vesting.
  • F2: These 51,000 RSUs were part of an 85,000-RSU award granted July 28, 2025 and moved from Table I to Table II in this filing.
  • F3: These 51,000 RSUs fully vested on July 28, 2026 (one-year anniversary); the remaining 34,000 RSUs from the award remain subject to vesting.

Context

• This was not an open-market purchase or sale: the sequence (RSU conversion then disposition to issuer) typically reflects settlement/withholding mechanics (shares withheld or surrendered to cover taxes) rather than a directional bet on the stock.
• The conversion showed no exercise cost (derivative price $0), consistent with RSU settlements.
• No 10b5-1 plan or late-filing issues are indicated in the information provided.